AFO-202 BRMG has been proven to attenuate CS caused by pro-inflammatory cytokines such as IL-6 while mounting anti-viral defence [54] by upregulating NK cells, macrophages and factors such as IL8, sFAS, type I IFN, IL and antibodies. The gene discussed is IL6; the disease is Cowden syndrome 1.